Payment overview · 2025
General Payments
$710.72
33 reported records · 12 companies
Healthcare provider profile · identity verified
Kamal P Singh, MD
Allopathic & Osteopathic Physicians|Internal Medicine · RUSSELLVILLE, KY · NPI 1902885759
Verified facts
What the public records show
CMS Open Payments records show Kamal P Singh, MD received $710.72 in general payments during 2025 across 33 reported records.
Amgen Inc. accounted for 30.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Prolia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 281 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Rybelsus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $216.83 | 30.5% | 10 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $111.29 | 15.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $84.29 | 11.9% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $61.76 | 8.7% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $53.86 | 7.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.93 | 6.6% | 3 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $44.84 | 6.3% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $29.00 | 4.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.65 | 2.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.36 | 2.2% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $15.11 | 2.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.80 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $710.72 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $163.34 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $84.29 | 5 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $57.05 | 1 | 2025 |
Source payment records
|
|||||
| Baylis Medical Company Radiofrequency Puncture Generator Normalized: baylis medical company radiofrequency puncture generator |
Device | Boston Scientific Corporation | $54.24 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $53.86 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $53.49 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $46.93 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $46.92 | 5 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $44.84 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $40.09 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $40.09 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $29.00 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $15.11 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 281 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 158 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
19 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
158 | 34 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
281 | 54 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1117 | 280 |
| Atorvastatin Calcium | Atorvastatin Calcium | 947 | 225 |
| Levothyroxine Sodium | Levothyroxine Sodium | 773 | 175 |
| Metoprolol Succinate | Metoprolol Succinate | 772 | 187 |
| Pantoprazole Sodium | Pantoprazole Sodium | 757 | 208 |
| Amlodipine Besylate | Amlodipine Besylate | 736 | 187 |
| Lisinopril | Lisinopril | 732 | 194 |
| Montelukast Sodium | Montelukast Sodium | 562 | 122 |
| Metoprolol Tartrate | Metoprolol Tartrate | 520 | 134 |
| Omeprazole | Omeprazole | 477 | 118 |
| Losartan Potassium | Losartan Potassium | 409 | 115 |
| Furosemide | Furosemide | 370 | 99 |
| Hydrochlorothiazide | Hydrochlorothiazide | 353 | 92 |
| Eliquis | Apixaban | 343 | 73 |
| Meloxicam | Meloxicam | 338 | 79 |
| Hydralazine Hcl | Hydralazine Hcl | 333 | 88 |
| Tamsulosin Hcl | Tamsulosin Hcl | 321 | 73 |
| Ozempic | Semaglutide | 281 | 54 |
| Famotidine | Famotidine | 277 | 78 |
| Escitalopram Oxalate | Escitalopram Oxalate | 267 | 73 |
| Ezetimibe | Ezetimibe | 265 | 66 |
| Simvastatin | Simvastatin | 264 | 60 |
| Buspirone Hcl | Buspirone Hcl | 248 | 68 |
| Lovastatin | Lovastatin | 248 | 58 |
| Clopidogrel | Clopidogrel Bisulfate | 226 | 61 |
| Glimepiride | Glimepiride | 214 | 53 |
| Carvedilol | Carvedilol | 210 | 47 |
| Jardiance | Empagliflozin | 210 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 208 | 79 |
| Allopurinol | Allopurinol | 206 | 44 |
| Nifedipine Er | Nifedipine | 202 | 57 |
| Fluticasone Propionate | Fluticasone Propionate | 201 | 75 |
| Metformin Hcl Er | Metformin Hcl | 189 | 57 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 186 | 45 |
| Prednisone | Prednisone | 180 | 137 |
| Duloxetine Hcl | Duloxetine Hcl | 176 | 45 |
| Tizanidine Hcl | Tizanidine Hcl | 174 | 56 |
| Farxiga | Dapagliflozin Propanediol | 173 | 44 |
| Sertraline Hcl | Sertraline Hcl | 166 | 46 |
| Spironolactone | Spironolactone | 163 | 39 |
| Trazodone Hcl | Trazodone Hcl | 160 | 49 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 158 | 34 |
| Warfarin Sodium | Warfarin Sodium | 155 | 20 |
| Metformin Hcl | Metformin Hcl | 149 | 36 |
| Finasteride | Finasteride | 143 | 37 |
| Potassium Chloride | Potassium Chloride | 142 | 40 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 132 | 33 |
| Pioglitazone Hcl | Pioglitazone Hcl | 128 | 42 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 121 | 25 |
| Benazepril Hcl | Benazepril Hcl | 120 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 109 | 32 |
| Nebivolol Hcl | Nebivolol Hcl | 105 | 27 |
| Paroxetine Hcl | Paroxetine Hcl | 99 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 98 | 19 |
| Gabapentin | Gabapentin | 97 | 44 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 96 | 31 |
| Diltiazem 24hr Er | Diltiazem Hcl | 94 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 92 | 27 |
| Sucralfate | Sucralfate | 88 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 85 | 20 |
| Trulicity | Dulaglutide | 84 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 81 | 20 |
| Januvia | Sitagliptin Phosphate | 80 | 17 |
| Cefuroxime | Cefuroxime Axetil | 79 | 71 |
| Glipizide Er | Glipizide | 79 | 18 |
| Xarelto | Rivaroxaban | 79 | 16 |
| Synthroid | Levothyroxine Sodium | 77 | 17 |
| Mounjaro | Tirzepatide | 76 | 17 |
| Celecoxib | Celecoxib | 75 | 25 |
| Donepezil Hcl | Donepezil Hcl | 75 | 19 |
| Tresiba Flextouch U-200 | Insulin Degludec | 75 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 72 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 70 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 69 | 23 |
| Bupropion Xl | Bupropion Hcl | 68 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | 25 |
| Valsartan | Valsartan | 65 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 19 |
| Enalapril Maleate | Enalapril Maleate | 63 | 15 |
| Tramadol Hcl | Tramadol Hcl | 63 | 27 |
| Repatha Sureclick | Evolocumab | 62 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 62 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 61 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 61 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | 16 |
| Minoxidil | Minoxidil | 61 | 14 |
| Alendronate Sodium | Alendronate Sodium | 60 | 13 |
| Alprazolam | Alprazolam | 54 | 19 |
| Ramipril | Ramipril | 54 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 53 | 12 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 53 | 14 |
| Atenolol | Atenolol | 51 | 14 |
| Pregabalin | Pregabalin | 51 | 24 |
| Breo Ellipta | Fluticasone/Vilanterol | 50 | suppressed |
| Linzess | Linaclotide | 50 | 11 |
| Telmisartan | Telmisartan | 50 | 12 |
| Clonidine Hcl | Clonidine Hcl | 49 | 15 |
| Ranolazine Er | Ranolazine | 47 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 46 | suppressed |
| Rybelsus | Semaglutide | 45 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 43 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 11 |
| Estradiol | Estradiol | 42 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 19 |
| Nystatin | Nystatin | 41 | 30 |
| Ondansetron Odt | Ondansetron | 41 | 18 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 40 | 11 |
| Bumetanide | Bumetanide | 39 | 12 |
| Meclizine Hcl | Meclizine Hcl | 39 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 39 | 14 |
| Propranolol Hcl Er | Propranolol Hcl | 38 | suppressed |
| Repatha Syringe | Evolocumab | 38 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 34 |
| Novolog Flexpen | Insulin Aspart | 37 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 22 |
| Praluent Pen | Alirocumab | 37 | suppressed |
| Memantine Hcl | Memantine Hcl | 35 | 12 |
| Promethazine Hcl | Promethazine Hcl | 35 | suppressed |
| Diazepam | Diazepam | 34 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 34 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | suppressed |
| Aripiprazole | Aripiprazole | 33 | 12 |
| Azithromycin | Azithromycin | 33 | 32 |
| Raloxifene Hcl | Raloxifene Hcl | 33 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | 12 |
| Theophylline Er | Theophylline Anhydrous | 32 | suppressed |
| Cefdinir | Cefdinir | 31 | 30 |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 31 | suppressed |
| Lorazepam | Lorazepam | 31 | suppressed |
| Nitroglycerin | Nitroglycerin | 31 | 21 |
| Divalproex Sodium Er | Divalproex Sodium | 30 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 29 | suppressed |
| Folic Acid | Folic Acid | 29 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 29 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Repaglinide | Repaglinide | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 26 | suppressed |
| Insulin Degludec Pen (U-200) | Insulin Degludec | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 23 |
| Gemfibrozil | Gemfibrozil | 23 | 11 |
| Mupirocin | Mupirocin | 23 | 21 |
| Naproxen | Naproxen | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Metolazone | Metolazone | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 15 |
| Temazepam | Temazepam | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 15 |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Prolia | Denosumab | 19 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 16 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 14 |
| Baclofen | Baclofen | 16 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Droplet Insulin Syringe | Syringe And Needle,insulin,1ml | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | 12 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Savella | Milnacipran Hcl | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Leflunomide | Leflunomide | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Cholestyramine Light | Cholestyramine | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | 11 |
| Estradiol (Twice Weekly) | Estradiol | 11 | suppressed |
| Teriparatide | Teriparatide | 11 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $710.72 · 33 records | Amgen Inc. | AREXVY, Baylis Medical Company Radiofrequency Puncture Generator, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FARAPULSE, Kerendia, Korlym, OTEZLA, Ozempic, REPATHA, Rybelsus, Senza, TRELEGY ELLIPTA, TZIELD, VERQUVO, VOQUEZNA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error